No Data
No Data
G1 Therapeutics, Pharmacosmos Planned Merger Advances as Antitrust Waiting Period Ends
Express News | Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
Catalyst Watch: Eyes on Jackson Hole, Target Earnings, and Canadian Rails Disruption
J.P. Morgan Maintains G1 Therapeutics(GTHX.US) With Hold Rating, Maintains Target Price $7.15
J.P. Morgan analyst Anupam Rama maintains $G1 Therapeutics(GTHX.US)$ with a hold rating, and maintains the target price at $7.15.According to TipRanks data, the analyst has a success rate of 45.7%
J.P. Morgan Upgrades G1 Therapeutics (GTHX) to a Hold
Catalyst Watch: Eyes on Walmart Earnings, the July CPI Print, and 13F Filings